Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lantheus HoldingsLNTH -1.35%80 Debt-to-Equity is 0.52 as of Mar. 2026, which is 4% below its 10-year median of 0.54. GuruFocus rates LNTH with a GF Score™ of 80/100 and a GF Value™ of $90.49 (Fairly Valued). The stock has 4 warning signs investors should review. Among 815 Drug Manufacturers companies, Lantheus Holdings ranks worse than 70.43% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Lantheus Holdings's Debt-to-Equity or its related term are showing as below:
LNTH'
s Debt-to-Equity Range Over the Past 10 Years
Min: -3.44 Med: 0.54 Max: 11.51
Current: 0.52
During the past 13 years, the highest Debt-to-Equity Ratio of Lantheus Holdings was 11.51. The lowest was -3.44. And the median was 0.54.
LNTH's Debt-to-Equity is ranked worse than 70.43% of 815
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs LNTH: 0.52
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Lantheus Holdings Debt-to-Equity Related Terms
Lantheus Holdings Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Lantheus Holdings's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LNTH vs HIMS, LQDA, AMRX: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantheus Holdings Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Lantheus Holdings's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantheus Holdings (LNTH) has a Debt-to-Equity of 0.52 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Lantheus Holdings and its competitors. This is near median its historical median of 0.54. According to the industry distribution chart, Lantheus Holdings ranks #574 out of 815 companies in the Drug Manufacturers industry, placing it in the top 70.4%.
Is Lantheus Holdings' Debt-to-Equity too high?
Lantheus Holdings' current Debt-to-Equity of 0.52 is near median its 10-year median of 0.54. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Lantheus Holdings' value of 0.52 is 85.7% above this industry median. Based on the distribution chart, Lantheus Holdings ranks #574 out of 815 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Lantheus Holdings has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lantheus Holdings' Debt-to-Equity compare to HIMS and LQDA?
According to the Drug Manufacturers industry distribution chart, Lantheus Holdings ranks #574 out of 815 companies for Debt-to-Equity. This places Lantheus Holdings in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Lantheus Holdings' value of 0.52 is 85.7% above this benchmark. While the company's 10-year median is 0.54 vs. the industry median of 0.28, Lantheus Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lantheus Holdings's current Debt-to-Equity of 0.52 is 85.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Lantheus Holdings and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lantheus Holdings's current Debt-to-Equity is 0.52, which is near median its own 10-year median of 0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantheus Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lantheus Holdings (LNTH) is currently considered Fairly Valued. The stock's GF Value™ is $90.49, compared to a current price of $99.57 — trading 10% above its estimated fair value. The current Debt-to-Equity is 0.52, which is near median its 10-year median of 0.54 and 85.7% above the Drug Manufacturers industry median of 0.28. Lantheus Holdings' overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Lantheus Holdings (LNTH), the current Debt-to-Equity is 0.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lantheus Holdings (LNTH) Overvalued in 2026?
Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued.
The current stock price of $99.57 is trading 10% above its estimated GF Value™ of $90.49.
GuruFocus considers Lantheus Holdings to be Fairly Valued.
Key valuation signals for LNTH:
Debt-to-Equity: 0.52 (near median its 10-year median of 0.54)
GF Value™: $90.49 vs. price of $99.57 (10% above fair value)
Industry Position: 85.7% above the Drug Manufacturers median (#574 of 815)
No single metric tells the full story. See the LNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
80GF Score
Get the complete analysis for LNTH
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LNTH has been successfully added to your 
